BaroSense Inc., a medical device company headquartered in Menlo Park, CA, focuses on the research and development of innovative, minimally invasive medical devices for the treatment of obesity - the largest global chronic disease in adults.
It is estimated that more than 250 million people suffer from obesity worldwide. Obesity has reached epidemic proportions in the US, affecting approximately 40 million US adults. The Obesity Association estimates that 300,000 unnecessary deaths a year in the US can be attributed to obesity. Obese persons are at an increased risk for diabetes, coronary heart disease, stroke, sleep apnea, stroke, gall bladder disease, several types of cancer, and certain musculoskeletal disorders.
BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.
"A wise man should consider that health is the greatest of human blessings."
~ Hippocrates
